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Abstract
Background—Protein energy malnutrition (PEM) increases susceptibility to infectious diseases, 
including influenza infection, but no studies have addressed the potential influences of PEM on the 
immunogenicity and protective efficacy of avian influenza A(H5N1) vaccine.
Methods—We investigated the role of PEM on vaccine-mediated protection after a lethal 
challenge with recombinant A(H5N1) virus using isocaloric diets providing either adequate 
protein (AP; 18% protein) or very low protein (VLP; 2% protein) in an established murine model 
of influenza vaccination.
Results—We demonstrated that mice maintained on a VLP diet succumb to lethal challenge at 
greater rates than mice maintained on an AP diet, despite comparable immunization regimens. 
Importantly, there was no virus-induced mortality in both VLP and AP groups of mice when either 
group was immunized with adjuvanted low-dose A(H5N1) subvirion vaccine.
Conclusions—Our results suggest that adjuvanted vaccination in populations where PEM is 
endemic may be one strategy to boost vaccination-promoted immunity and improve outcomes 
associated with highly pathogenic A(H5N1).
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Malnutrition is a significant public health concern, with protein energy malnutrition (PEM) 
being the most lethal form of malnutrition [1]. Defined as an imbalance between food intake 
(protein and energy) and the levels necessary for a host to achieve optimal growth [2, 3], 
PEM affects every fourth child worldwide and is implicated in at least half of the 10.4 
million child deaths annually [4]. Although 95.9% of the world’s undernourished population 
of 826 million are in developing countries [5], the elderly, specifically those hospitalized or 
living in long-term care facilities, are significantly affected by malnutrition [6, 7].
The ongoing circulation of highly pathogenic avian influenza A (H5N1) virus in poultry and 
its intermittent ability to infect humans, particularly in endemic parts of the globe, poses an 
imminent threat to global health (http://www.cdc.gov/flu/avianflu/h5n1-people.htm). Since 
2003, a total of 846 human cases of confirmed avian influenza A (H5N1) have been reported 
to the World Health Organization, with >53% (449 cases) resulting in death [8]. Serious 
illness, high fatality rates, and the ability for influenza viruses to rapidly undergo mutation 
as a result of antigenic shift underscore concerns about a potential A(H5N1) pandemic. 
Moreover, lack of immunity to A(H5N1) in humans makes vaccination the most effective 
prophylactic strategy for counteracting transmission during an A(H5N1) pandemic.
PEM has been associated with increased incidence of infections, including influenza [1, 3, 
9]. Given the global burden of PEM, and the current epidemiological demographic of 
A(H5N1), it is important to understand the implications of nutritional inadequacies on the 
immunogenicity and efficacy of A(H5N1) vaccine. A(H5N1) vaccine is inherently less 
immunogenic than antigens routinely included in the seasonal influenza vaccines [10]. 
Consequently, higher doses of antigen and/or other vaccine strategies are necessary to elicit 
effective protection against an emerging avian influenza virus such as A(H5N1), which may 
constitute the use of an adjuvanted system to limit the amount of antigen and improve the 
host immune response. More recently, safety and immunogenicity studies have underscored 
the feasibility of using adjuvants for improving immunogenicity of A(H5N1) vaccines [11, 
12].
In the present study, the murine model was used to ascertain the impact of PEM on 
adjuvanted A(H5N1) (A/Vietnam/1203/2004/H5N1; clade 1 monovalent vaccine) 
vaccination and subsequent lethal challenge. Weanling mice were fed isocaloric diets 
supplemented with either adequate (18%) or very low (2%) levels of protein [9, 13], 
followed by different vaccination regimens and viral challenge with a lethal dose of rgH5N1, 
a reverse genetics–derived A(H5N1) (A/Vietnam/1203/2004) virus on A/PR/8/1934 
background. Our findings illustrate enhanced protection after challenge and suggest a role 
for adjuvanted vaccines in decreasing the susceptibility and improving influenza (H5N1)–
induced outcomes, specifically in malnourished settings.
MATERIALS AND METHODS
Mice and Diets
Four-week-old female C57BL/6 mice were purchased from the Jackson Laboratory, 
quarantined for 3 days, and randomly assigned to isocaloric diets (Harlan Laboratories) 
containing either 18% or 2% protein, defined as adequate protein (AP) and very low protein 
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(VLP), respectively. The composition and caloric content of the diets used in the study have 
been described elsewhere [9]. Also as described elsewhere [9], mice were randomly 
assigned, and the amount of food provided to the control group of mice (AP group) was 
matched to that consumed by the experimental group (VLP group) to confirm comparable 
feed consumption. Based on this, we replenished the same amount of feed every 3 days and 
weighed the amount of feed consumed (per week) by the AP and VLP groups of mice. All 
studies contained herein were approved by the Centers for Disease Control and Prevention 
(CDC) Institutional Animal Care and Use Committee and carried out in a facility accredited 
by the Association for Assessment and Accreditation of Laboratory Animal Care 
International.
Immunizations
Five weeks after onset of the postisocaloric diet onset, mice were vaccinated intramuscularly 
with influenza A virus monovalent vaccine (A/Vietnam/1203/2004/H5N1, clade 1; prepared 
by Sanofi Pasteur for use in humans, obtained through the Biomedical Advanced Research 
and Development Authority), hereafter referred to as H5 (A/Vietnam/1203/2004/H5N1)-HA 
(hemagglutinin), containing either 3 or 10 μg of H5-HA in a total volume of 100 μL per 
mouse. Adjuvanted groups were vaccinated with 3 μg of H5-HA formulated with an oil-in-
water nanoemulsion adjuvant system [14] at a concentration of 1:,1 in a total volume of 100 
μL per mouse. The nanoemulsion adjuvant consisted of squalene and α-tocopherol, Tween 
20, and phosphate-buffered saline (PBS). The detailed protocol for preparation of an oil-in-
water emulsion- based adjuvant system developed in our laboratory is described elsewhere 
[14]. Each mouse in the adjuvant control group was administered 100 μL of adjuvant 
formulated with PBS in a 1:1 concentration. Two weeks later, mice received a booster 
immunization dose, according to the same procedure used for primary immunization.
Hemagglutination Inhibition Assay
Mouse serum samples were was treated overnight with receptor- destroying enzyme (Denka 
Seiken) and tested for reactivity to rgH5N1 virus using the standard hemagglutination 
inhibition (HI) assay with 0.5% horse red blood cells (RBCs), as described elsewhere [15]. 
In short, 25 μL of cold ×1 PBS was added to the wells of a 96-well V-bottom plate 
(Corning). Receptor-destroying enzyme–treated serum samples (25 μL) was then added to 
each column and serially diluted. Eight hemagglutination units of rgH5N1 virus were added 
to each well and incubated at room temperature for 60 minutes. Finally, 50 μL of 0.5% horse 
RBCs in ×1 PBS was added to each well and incubated at room temperature for 60 minutes. 
The HI titer was recorded as the serial dilution of serum showing complete HI.
Virus Infection
For virus challenge studies, we used rgH5N1 (A/Vietnam/1203/2004), a virus strain 
containing the H5-HA gene (with a modified basic amino acid cleavage site) and the N1 
neuraminidase gene from A(H5N1) virus (A/Vietnam/1203/2004) on an A/PR/8/34 
background. Details of generation and propagation of rgH5N1 have been described 
elsewhere [16]. Briefly, rgH5N1 virus was propagated in 10-day-old embryonated chicken 
eggs and stored at –80°C. The median lethal dose of rgH5N1 (equivalent to 6 × 105 plaque-
forming units/50 μL) was determined in mice fed an AP diet. For virus challenge studies, 
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mice were deeply anesthetized with 2,2,2-tribromoethanol in tert-amyl alcohol (Avertin; 
Sigma-Aldrich) before intranasal inoculation with 4 times the median lethal dose of 
rgH5N1. All mice that lost ≥25% preinfection body weight were humanely euthanized, 
according to CDC Institutional Animal Care and Use Committee guidelines.
Lung Viral Titer Quantitation
Lungs were aseptically removed on day 4 after infection and stored at –80° C. Samples were 
thawed and homogenized in antibiotic-supplemented PBS on the day of assessment. As 
described elsewhere [9], serial dilutions were titrated in eggs to determine virus infectivity 
(limit of detection, 101.5 egg infectious dose 50 [EID50]/mL). Allantoic fluid from the 
inoculated eggs was added to wells containing 0.5% turkey RBCs in PBS. Virus titers were 
calculated using the method described by Reed and Muench [17] and are expressed as the 
mean log10 EID50/mL (with standard error of the mean).
Lung Cytokine Assay
Lung homogenates (see methods for lung viral titer quantitation, above) were added in 
duplicate to a Bioplex plate (Bio-Rad Laboratrories) previously coated with anti-mouse 
antibody– conjugated beads specific for interleukin 1β, 6, and 12p40 (IL- 1β, IL-6, and 
IL-12p40), interferon (IFN) γ, and tumor necrosis factor (TNF) α. Bioplex plate was 
processed and read according to the manufacturer’s protocol on a Bioplex 200 Array Reader 
(Bio-Rad Laboratrories).
Statistical Analysis
All statistical analyses were performed using GraphPad Prism version 5.0 software 
(GraphPad Software). Analysis of variance was used when >2 groups were being compared, 
with post hoc Tukey multiple-comparison testing to delineate significance among 
experimental groups at a 95% confidence interval. Lung viral titer, lung cytokine 
concentration, morbidity rate, and serum HI titer were presented as means with standard 
deviations. All differences were considered statistically significant when at P< .05.
RESULTS
Serum HI Responses in AP and VLP Diet Groups of Mice
Earlier studies using 2 isocaloric diets showed that, compared with a diet containing AP, the 
VLP diet increased susceptibility to influenza infection [9]. In the current study, to 
determine the effects of PEM on influenza vaccination, we used AP and VLP diets on 
weanling mice, followed by immunizations with different doses of H5-HA or adjuvanted-
H5-HA. First, as shown in Figure 1, weanling mice maintained on an AP or VLP diet were 
examined weekly for feed consumption and body weight gain over a period of 3 weeks. As 
shown in Figure 1, whereas mice maintained on an AP diet regimen gained body weight, the 
VLP group showed significant growth retardation (percentage body weight gain) (Figure 
1A), despite comparable levels of feed consumption in the 2 groups (Figure 1B). The 
difference in percentage body weight between the groups was evident as early as 1 week 
after initiation of custom diets and markedly different by 3 weeks. In earlier studies using 
AP and VLP diets, we found that mice fed a VLP diet show a significant decrease in serum 
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leptin levels, a key determinant of PEM [18, 19]. Next, as shown in Supplementary Figure 1, 
both groups of mice (AP and VLP) received different doses of H5-HA or adjuvanted H5-HA 
at week 9, followed by booster immunization at week 11.
Serum samples were collected from all groups of mice before and 2 weeks after booster 
immunization to assess rg-H5N1– specific HI response. Serum samples collected after 
primary immunization did not show detectable HI titer in any experimental groups (data not 
shown). Similarly, serum samples from mice receiving booster immunization with low (3-
μg) dose of H5-HA did not show appreciable levels of HI titer (Figure 1C; left and right). 
Moreover, with the exception of 1 mouse in the AP group, serum samples from both groups 
of mice immunized with a high (10-μg) dose of H5-HA did not show detectable HI titer. 
Interestingly, both AP and VLP groups immunized with adjuvanted H5-HA showed 
significantly higher HI titer than groups immunized with H5-HA alone (Figure 1C; left and 
right). Moreover, the levels of HI titer induced after booster immunization were comparable 
between the AP and VLP groups (Figure 1C; left and right). Mice receiving adjuvant alone 
did not show any detectable HI titer.
Immunization With an Oil-In-Water Nanoemulsion Adjuvant Leads to Enhanced Survival of 
VLP Diet Fed Mice Challenged With rgH5N1
The immunization regimen used in this study demonstrated the potential for an adjuvanted 
vaccine regimen to induce HI antibody response in mice maintained on either an AP or a 
VLP diet. To determine whether the adjuvant-induced effect on antibody response could 
help protect against lethal virus challenge, both AP and VLP groups were challenged with 
rgH5N1 virus 2 weeks after booster immunization. Interestingly, in both AP and VLP 
groups, all the mice that received adjuvanted H5-HA survived the lethal viral challenge 
(Figure 2A, left and right). Furthermore, groups of mice on the AP diet that received a low 
(3-μg) or high (10-μg) dose of H5-HA also showed significant survival (Figure 2A, left). 
However, mice fed a VLP diet that received either low- or high-dose H5-HA showed 
significantly lower survival levels than mice receiving adjuvanted H5-HA (Figure 2A, right). 
Mice receiving adjuvant alone showed poor survival in both AP and VLP groups (Figure 2A, 
left and right).
Because the immunization regimen used in this study could influence protection by 
modulating virus clearance, we determined the virus titer and key inflammatory mediators in 
the lung tissue on day 4 after viral challenge. As shown in Figure 2B, in both groups (AP 
and VLP), mice that received adjuvanted H5-HA showed 2–3-log lower levels of virus titer 
than mice treated with H5-HA or adjuvant alone. An increase in the survival rate of mice 
immunized with H5-HA in the AP group prompted us to investigate differences in antiviral 
and inflammatory mediators. Analysis of antiviral cytokine (IFN-γ) and inflammatory 
(IL-1β, IL-6, IL-12p40, and TNF- α) mediators showed that, compared with the AP group, 
the VLP group showed lower levels of all the inflammatory markers (Supplementary Figure 
2). However, with the exception of IFN-γ in the AP group, for which mice receiving 
adjuvanted vaccine had significantly lower amounts of cytokine than those receiving H5-
HA, there was no difference in any inflammatory marker among the 4 treatment groups for 
either AP or VLP diet–fed mice (Supplementary Figure 2).
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DISCUSSION
The reciprocal relationship between nutrition, specifically as it relates to protein deficiency, 
and vaccination has been appreciated for some time [20, 21]. In this study, using the mouse 
model of influenza vaccination, we examined the impact of PEM, a major form of 
malnutrition in developing countries, on protection against A(H5N1) infection. Because 
A(H5N1) vaccine (H5-HA) is poorly immunogenic [10], we used 2 different doses of 
vaccine and an oil-in-water nanoemulsion as adjuvant for immunizations. We found that 
while both doses of H5-HA failed to elicit HI response in the AP and VLP groups of mice, 
adjuvanted H5-HA induced comparable HI responses in AP and VLP groups of mice. 
Furthermore, adjuvanted H5-HA provided complete protection against lethal viral challenge 
even in the VLP group, which previously has been shown to be highly susceptible to 
influenza (H1N1) infection [9]. Adjuvanted H5-HA– mediated protection was also reflected 
by >2-log decrease in virus titer in both AP and VLP groups. Taken together, these results 
demonstrate that malnourished hosts may not be able to respond effectively to H5-HA–
based vaccines and further highlights the need for an adjuvanted vaccine to overcome the 
PEM-induced immune deficits, and achieve comparable protection in healthy and 
malnourished hosts.
Earlier studies using the mouse model of PEM have shown the utility of the model for 
studying the impact of PEM on viral infections [9, 13, 18]. Although in the current study we 
used body weight as a marker to assess malnutrition in the VLP group, we and others have 
found low levels of serum leptin in VLP-fed mice to be yet another marker for diet-induced 
PEM [9, 18]. However, despite our efforts to use the same source of experimental mice and 
isocaloric custom diets as in earlier [9] and more current studies, we observed in the present 
study a relatively higher gain in body weight in the AP groups and a higher loss in the VLP 
groups within 3 weeks after study initiation. Nonetheless, change in percentage body weight 
gain over time in the VLP group was not due to any difference in consumption, because feed 
intake was comparable between the AP and VLP groups. Both diet groups were monitored 
routinely and were in adequate health until the time of viral challenge.
Considering the poor immunogenicity of HA, several experimental approaches have been 
tested for improving the immunogenicity and efficacy of A(H5N1) vaccines [12, 22]. Some 
of these approaches include high-dose vaccination, dose-sparing regimens, different 
formulations of adjuvanted vaccine, and different routes of vaccination [23–26]. In this 
study, we used 3 or 10 μg of H5-HA for the immunization protocol because our preliminary 
studies with 10-, 3-, 1-, and 0.3-μg doses of H5-HA administered intra-muscularly in 6-
week-old mice showed poor immunogenicity in the absence of an adjuvant (S.S., W.C., S.G., 
unpublished observations). Furthermore, in the current study, even after boosting, neither 
dose elicited any significant HI response, a key parameter for assessing protection from viral 
challenge in mice. Interestingly, adjuvanted H5-HA was able to induce comparable HI 
response in both AP and VLP groups of mice. Furthermore, comparable HI titers between 
AP and VLP groups were also reflected in complete protection of mice from lethal viral 
challenge and >2-log reduction of virus titer in the lung tissue. However, the AP group that 
received either high- or low-dose H5-HA alone also showed significant survival from viral 
challenge, compared with a poor survival rate for a similar immunization regimen in the 
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VLP group, a difference probably due to differences in weight gain over the course of 
experiment and increased susceptibility of mice fed a VLP diet to the virus dose used in the 
study.
Notably, no HI titer was detectable in the AP groups of mice immunized with either high- or 
low-dose H5-HA. The reverse genetics–derived H5N1 virus (rg-H5N1stock) used in the 
current study showed a low concentration of hemagglutination units (64–128 
hemagglutination units) and low virus stock titer (106 plaque-forming units/mL), which 
restricted its use in our study for carrying out microneutralization assays [27], another 
sensitive neutralization assay for characterizing virus-specific antibody responses. It is 
possible that other H5-HA–mediated protective mechanisms may be responsible for 
enhanced survival of AP group of mice from lethal challenge. Alternatively, because a 
similar effect was not seen in the VLP group, a higher protein (AP) diet could be inducing 
additional immune stimulatory pathways, contributing to survival mechanisms. Aptly, lung 
homogenates from the AP groups of mice showed higher levels of IL-1β, IL-6, IL-12p40, 
IFN-γ, and TNF-α (Supplementary Figure 2) cytokines than the VLP groups. Further 
studies involving antibody-mediated protection by passive transfer of serum as well as 
characterization of inflammatory responses of cell types could aid in defining the immune 
mechanisms involved in these immunization protocols in the face of AP and VLP diets.
Some ongoing clinical trials have aimed at understanding immune responses to adjuvanted 
A(H5N1)-specific influenza vaccine in healthy populations [28]. Adjuvanted influenza 
vaccines including an adjuvant containing oil-in-water emulsion of squalene oil are 
approved for use among persons aged ≥65 years [29]. Notably, results from meta-analysis of 
several clinical trials found no safety concerns associated with use of adjuvanted vaccines 
[30]. However, both experimental and preclinical studies addressing the safety and efficacy 
of adjuvanted vaccines in children and older population at different geographic locations are 
needed before the application of such strategies to PEM settings can be considered. Some 
studies have also investigated the relationship between influenza vaccine responses and 
individuals’ nutritional status [31–34].
However, vaccination studies involving PEM, yet another major risk factor for increased 
susceptibility to influenza infection and mortality [35, 36], are necessary to elucidate PEM-
induced and vaccine-specific immune deficits. Such studies will help in devising novel 
vaccine strategies to achieve optimal responses against seasonal and potentially pandemic 
A(H5N1) infections. Given the high prevalence of PEM in underdeveloped countries, and 
different forms of PEM such as kwashiorkar and marasmus [37], identification of 
populations manifesting different forms and degree of PEM (eg, mild vs moderate or 
moderate vs severe) is critical for initiation of such studies and work toward developing safe 
and efficacious vaccination strategies. In the present study, we used custom diets 
representing either “adequate” or “severe” deficiency in protein-derived energy to address 
the effects of PEM in a mouse model of influenza vaccination. Because PEM in humans can 
also involve mild-to-moderate protein deficiencies, studies using additional protein diets as 
well as immunization strategies that elicit both antibody and cell-mediated immune 
responses in mice and other relevant animal models are interesting areas for further 
investigation.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Weekly body weight gain, feed intake, and hemagglutination inhibition (HI) titer in mice fed 
diets with adequate protein (AP) or very low protein (VLP). A, Change in percentage body 
weight gain over 3 weeks. B, Weekly feed intake. C, D, Serum HI titers in AP and VLP 
groups treated with H5-HA, adjuvanted H5-HA, or adjuvant. Data in all 4 panels represent 
results from 2 experiments (20 mice per group). Values in A and B represent means with 
standard deviations; in C, each symbol represents an individual mouse from 2 experiments 
with 10–14 mice per group, and horizontal lines represent mean group values.
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Figure 2. 
Survival rate and lung virus titer in response to immunization and lethal viral challenge in 
mice fed diets with adequate protein (AP) or very low protein (VLP). A, AP (left) and VLP 
(right) groups of mice receiving HA, adjuvanted HA, or adjuvant alone were assessed for 
protection from lethal (rgH5N1) viral challenge. Survival rates for AP and VLP groups are 
shown; data represent results from 2 independent experiments. B, Lung tissues harvested 
from mice on the AP or VLP diets at day 4 after viral challenge were homogenized and 
assayed for virus titer, as described in Materials and Methods. Data represent means and 
standard deviations from 2 independent experiments. The differences in survival percentage 
by treatment were statistically significant, as follows: AP groups: 3 μg of H5 (A/Vietnam/
1203/2004/H5N1)-HA (hemagglutinin) vs adjuvant, P < .01; 10 μg of H5-HA vs adjuvant, P 
< .05; 3 μg of H5-HA plus adjuvant vs adjuvant alone, P < .001. VLP groups: 3 μg of H5-
HA plus adjuvant vs adjuvant alone, 3 μg of H5-HA vs 3 μg H5-HA plus adjuvant, and 10 
μg of H5-HA vs 3 μg of H5-HA plus adjuvant, all P < .001. Abbreviation: EID50, egg 
infectious dose50.
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